Abstract
BACKGROUND: Although measurement of haemoglobin A1c has become the cornerstone for diagnosing diabetes mellitus in routine clinical practice, the role of this biomarker in reflecting long-term glycaemic control in patients with chronic kidney disease has been questioned.
METHODS: Consensus review paper based on narrative literature review.
RESULTS: As a different association between glycaemic control and morbidity/mortality might be observed in patients with and without renal insufficiency, the European Renal Best Practice, the official guideline body of the European Renal Association-European Dialysis and Transplant Association, presents the current knowledge and evidence of the use of alternative glycaemic markers (glycated albumin, fructosamine, 1,5-anhydroglucitol and continuous glucose monitoring).
CONCLUSION: Although reference values of HbA1C might be different in patients with chronic kidney disease, it still remains the cornerstone as follow-up of longer term glycaemic control, as most clinical trials have used it as reference.
| Original language | English |
|---|---|
| Journal | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association |
| Volume | 29 |
| Issue number | 12 |
| Pages (from-to) | 2167-77 |
| Number of pages | 11 |
| ISSN | 0931-0509 |
| DOIs | |
| Publication status | Published - Dec 2014 |
Fingerprint
Dive into the research topics of 'Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population?'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS